NCT03956979 (ASTORIA) is a Phase 2 clinical trial of JM-010 group A in Dyskinesias, sponsored by Contera Pharma.

Who is sponsoring NCT03956979?

NCT03956979 is sponsored by Contera Pharma.

What drugs are being tested in NCT03956979?

Interventions in NCT03956979: JM-010 group A, JM-010 group B, Placebos.

What condition does NCT03956979 study?

NCT03956979 studies Dyskinesias.

Is NCT03956979 still recruiting?

NCT03956979 is currently completed. Last updated 17 June 2024.

Last reviewed 2024-06-17 · How we verify

NCT03956979: ASTORIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Completed Phase 2 Last updated 17 June 2024

What this trial tests

Phase 2 trial testing JM-010 group A in Dyskinesias in 89 participants. Completed in 21 March 2024.

Timeline

22 July 2019

Primary endpoint
7 March 2024

21 March 2024

Quick facts

Lead sponsor	Contera Pharma
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	89
Start date	22 July 2019
Primary completion	7 March 2024
Estimated completion	21 March 2024
Sites	5 locations across France, Italy, Germany, South Korea, Spain

Drugs / interventions tested

JM-010 group A — full drug profile →
JM-010 group B — full drug profile →
Placebos — full drug profile →

Conditions studied

Dyskinesias — all drugs for Dyskinesias →

Sponsor

Contera Pharma — full company profile →

Who can join

Adults 18 to 85, any sex, with Dyskinesias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia.
Fabbrini A, Guerra A. · · 2021 · cited 34× · PMID 33953618 · DOI 10.2147/jep.s265282
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
Di Luca DG, Reyes NGD, Fox SH. · · 2022 · cited 21× · PMID 35841520 · DOI 10.1007/s40265-022-01747-7
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Jing XZ, Yuan XZ, Luo X, Zhang SY, et al · · 2023 · cited 21× · PMID 35193486 · DOI 10.2174/1570159x20666220222150811
Parkinson's disease therapy: what lies ahead?
Wolff A, Schumacher NU, Pürner D, Machetanz G, et al · · 2023 · cited 19× · PMID 37147404 · DOI 10.1007/s00702-023-02641-6
CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
McFarthing K, Prakash N, Simuni T. · · 2019 · cited 12× · PMID 31356217 · DOI 10.3233/jpd-199002
The effect of 5-HT<sub>1A</sub> receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats.
Vegas-Suárez S, Aristieta A, Requejo C, Bengoetxea H, et al · · 2021 · cited 4× · PMID 33686657 · DOI 10.1111/bph.15437
Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation.
Vegas-Suárez S, Morera-Herreras T, Requejo C, Lafuente JV, et al · · 2022 · cited 3× · PMID 36133803 · DOI 10.3389/fphar.2022.953652

Verify or expand the search:

Other recruiting trials for Dyskinesias

Currently open trials in the same condition.

NCT07023224 — Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) · recruiting
NCT06585605 — A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia · recruiting
NCT05317390 — Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03956979 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Contera Pharma
Last refreshed: 17 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03956979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing